Clinical Research Directory
Browse clinical research sites, groups, and studies.
Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+
Sponsor: The Eye Associates
Summary
Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs Phase 2 will be a prospective, randomized, unmasked, comparative, multi-site study with 90 days of follow up. Subjects will be randomized in a 1:1 manner to LAL+ or Clareon VIvity Toric IOLs.
Key Details
Gender
All
Age Range
45 Years - Any
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2024-10-15
Completion Date
2026-08-01
Last Updated
2024-08-28
Healthy Volunteers
No
Conditions
Interventions
LAL+
LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.
Clareon Vivity Toric IOL
Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
Locations (1)
The Eye Associates of Manatee, LLP
Bradenton, Florida, United States